New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...

MannKind (MNKD) and Cipla announced that the Central Drugs Standard Control Organisation in India has approved Afrezza Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing ...